Prediction of mortality in patients with coronary artery disease undergoing vasodilator stress testing:: A comparison between 99mTc-tetrofosmin and 99mTc-sestamibi

被引:1
|
作者
Adams, George L.
Shaw, Linda K.
Tuttle, Robert H.
Hanson, Michael W.
Pagnanelli, Robert
Borges-Neto, Salvador [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA
关键词
vasodilator; SPECT; prognosis;
D O I
10.1097/MNM.0b013e328174442d
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To compare the prognostic ability of the imaging agents Tc-99m-sestamibi versus Tc-99m-tetrofosmin to predict mortality outcomes in patients with documented coronary artery disease and undergoing vasodilator stress testing. Materials and methods The study included 2147 consecutive patients who underwent rest and stress single photon emission computed tomographic (SPECT) examination with either 99mTc-sestamibi (n= 1128) or Tc-99m-tetrofosmin (n=1019). Information relating to all-cause death and cardiovascular death was collected over a 4-year study period. Unadjusted Kaplan-Meier estimates were compared for the two imaging agents. Cox proportional hazard models were examined to determine the incremental contribution of SPECT sum stress score (SSS) and the imaging agent after adjusting for clinical and demographic characteristics. Additionally, the interaction between SSS and agent was examined to determine if the effect of SSS on prognosis was different for the two agents. Results Vasodilator agents were used for stress testing in all patients who received Tc-99m-tetrofosmin and Tc-99m-sestarnibi. Despite differences in patient risk factors Kaplan-Meier estimates were similar for the two groups of patients. Resulting P-values for differences between models for the end points of (1) death from any cause and (2) cardiovascular death showed that SSS combined with clinical index was significantly better than a model that adjusted for only baseline characteristics (P < 0.0001 for both endpoints). The addition of imaging agent (Tc-99m-tetrofosmin or 99mTc-sestamibi) to the model containing both SSS and the clinical characteristics did not show further significant improvement (P=0.62, P=0.96 for death from any cause and cardiovascular death, respectively). Conclusion The type of clinically available Tc-99m-labelled myocardial perfusion agents did not affect interpretation of results for prognostic assessment.
引用
收藏
页码:457 / 463
页数:7
相关论文
共 50 条
  • [1] Efficiency comparison between 99mTc-tetrofosmin and 99mTc-sestamibi myocardial perfusion studies
    Ravizzini, GC
    Hanson, MW
    Shaw, LK
    Wong, TZ
    Hagge, RJ
    Pagnanelli, RA
    Jain, D
    Lima, HS
    Coleman, RE
    Borges-Neto, S
    NUCLEAR MEDICINE COMMUNICATIONS, 2002, 23 (03) : 203 - 208
  • [2] Detection of mild to moderate coronary artery disease: Comparison between 99mTc-Sestamibi and 99mTc-Tetrofosmin SPECT imaging with dipyridamole.
    Taillefer, R
    Soman, P
    DePuey, EG
    Udelson, JE
    Lahiri, A
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 86P - 86P
  • [3] Comparison of 99mTc-sestamibi and 99mTc-tetrofosmin washoutratesfrom parathyroid and thyroid glands
    Athanasoulis, T.
    Valsamaki, P.
    Karantanis, D.
    Daramaras, A.
    Jianakopoulou, P.
    Katsoulis, A.
    Zerva, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S232 - S233
  • [4] A comparison of stress 99mTc-Sestamibi and 99mTc-tetrofosmin: visually quality of the images and the need for repeated scans
    Hansen, G.
    Jensen, B. T.
    Kristensen, C.
    Kalia, S.
    Gerke, O.
    Vestergaard, S.
    Johansen, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S499 - S499
  • [5] 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?
    Fröberg, AC
    Valkema, R
    Bonjer, HJ
    Krenning, EP
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (02) : 193 - 196
  • [6] 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?
    Alida C. Fröberg
    Roelf Valkema
    Jaap H. Bonjer
    Eric P. Krenning
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 193 - 196
  • [7] Outcome prediction in patients at high risk for coronary artery disease:: Comparison between 99mTc tetrofosmin and 99mTc sestamibi
    Borges-Neto, S
    Tuttle, RH
    Shaw, LK
    Smith, WT
    Jain, D
    Coleman, RE
    Whellan, D
    RADIOLOGY, 2004, 232 (01) : 58 - 65
  • [8] Differences between 99mTc-sestamibi and 99mTc-tetrofosmin uptake in thyroid and salivary glands:: comparison with 99mTc-pertechnetate in 86 subjects
    Giordano, A
    Meduri, G
    Marozzi, P
    Rubini, G
    Burroni, L
    Cappagli, M
    NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (03) : 321 - 326
  • [9] Performance of 99mTc-tetrofosmin versus 99mTc-sestamibi in murine myocardial perfusion studies
    Vrachimis, Alexis
    Hermann, Sven
    Schober, Otmar
    Schafers, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] Comparison of the kinetics of 99mTc-sestamibi and 99mTc-tetrofosmin in a multidrug-resistant tumour cell line
    Utsunomiya, K
    Ballinger, JR
    Zhang, XG
    Su, ZF
    Tsuchida, T
    Ichise, M
    RADIOLOGY, 1999, 213P : 162 - 162